Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) represented a move of 2.91 percent or $-0.3 per share and closed its previous day trading session at $10.24. 299019 Shares were traded in the last trading session with an Average Volume of 631.46 Million Shares. The stock currently has a Market Capitalization of 271.97 Million.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
The stock traded between $ 9.69 and $44.00 over 1-Year time period showing its price to sales ratio of 12.77. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-33.89 and 200-Day Simple Moving Average of $-56.22. Its Price to Free Cash Flow is 0 and Price to Book of 2.44.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) reported its Actual EPS of $-1.22/share. The analysts offering Earnings Estimates for the company were believing that Adamas Pharmaceuticals, Inc. could bring EPS of $-1.34/share. The difference between Actual EPS and Estimated EPS was 0.12 Percent. Thus showing an Earnings Surprise of 9 Percent.
Energen Corporation (NYSE:EGN)
In the last trading session, Energen Corporation (NYSE:EGN) added its value by 0% closing at the price of $72.12. The stock currently has market capitalization of 7.03 Billion, with average volume of 1.39 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Energen Corporation (NYSE:EGN) is showing beta of 0. This particular value of beta suggests that Energen Corporation (NYSE:EGN) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Energen Corporation (NYSE:EGN) is at $4.32.
The stock currently has RSI of 46.85. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Energen Corporation is an independent oil and gas exploration and production company that operates exclusively in the Permian Basin of west Texas and New Mexico. Energen is focused on return-driven growth from the drilling and development of multiple horizontal shale formations in the Delaware and Midland basins using its Generation 3 frac design. The majority of the company’s Gen 3 wells have been drilled in multi-zone patterns and completed in batches at original reservoir pressure. The Corporation’s utility subsidiary, Alabama Gas Corporation, is the largest natural gas distribution utility in the State of Alabama. The Corporation’s oil and gas exploration and production activities are conducted by its subsidiary, Taurus Exploration, Inc. and its subsidiary.